Skip to main content
SpringerLink
Log in
Book cover

Mammakarzinom Interdisziplinär pp 228–246Cite as

Systemische Therapie des metastasierten Mammakarzinoms

  • Chapter

  • 2490 Accesses

Zusamenfassung

Das metastasierte Mammakarzinom ist im Allgemeinen nicht kurabel. Ungefähr ein Drittel aller Frauen, die an einem Mammakarzinom erkranken, erleben im weiteren Verlauf der Erkrankung eine Fernmetastasierung. Die mittlere Überlebensdauer nach Auftreten von Metastasen wird mit 18–24 Monaten angegeben. In Abhängigkeit von klinischen Faktoren wie dem krankheitsfreien Intervall nach Primärtherapie und Art und Ausdehnung des Organbefalls kann die mediane Überlebenszeit jedoch stark variieren.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   29.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   79.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Esteva FJ, Valero V, Booser D (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER2 overexpressing metastatic breast cancer. J Clin Oncol 20: 1800–1808

    Article  CAS  PubMed  Google Scholar 

  • Ahmann DL, Schaid DJ, Bisel HF, Hahn RG, Edmonson JH, Ingle JN (1998) The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug. J Clin Oncol 5: 1928–1932

    Google Scholar 

  • Albain KS, Nag S, Calderillo-Ruiz G et al. (2004) Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. J Clin Oncol 22: 510 (Abstract)

    Google Scholar 

  • Barton-Burke M (1999) Gemcitabine — a pharmalogic and clinical overview. Cancer Nurs 22: 176

    Article  CAS  PubMed  Google Scholar 

  • Baselga J, Cortes J, Fumoleau P, Petrella T, Gelmon K, Verma S, Pivot X, Ross G, Szado T, Gianni L (2009) Pertuzumab and trastuzumab: re-responses to 2 biological agents in patients with HER2-positive breast cancer which had previously progressed during therapy with each agent given separately: a new biological and clinical observation. Cancer Res 69(24 Suppl): Abstract 5114

    Article  Google Scholar 

  • Bastholt L, Dalmark M, Gjedde SB et al. (1996) Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 14: 1146–1155

    CAS  PubMed  Google Scholar 

  • Bennett JM, Muss HB, Doroshow JH, Wolff S, Krementz ET, Cartwright K, Dukart G, Reisman A, Schoch I (1988) A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 6: 1611–1620

    CAS  PubMed  Google Scholar 

  • Bonneterre J et al. (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol 18: 3748–3757

    CAS  PubMed  Google Scholar 

  • Brodie AM, Njar VC (1998) Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications. J Steroid Biochem Mol Biol 66: 1–10

    Article  CAS  PubMed  Google Scholar 

  • Brufsky A, Bondarenko IN, Smirnov V, Hurvitz S, Perez E, Ponomarova O, Vynnychenko I, Swamy R, Mu H, Rivera R (2009) RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer. SABCS, Abstract 42

    Google Scholar 

  • Buchanan RB et al. (1986) A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4: 1326–1330

    CAS  PubMed  Google Scholar 

  • Burstein H, Kuter I, Campos SM et al. (2001) Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19: 2722–2730

    CAS  PubMed  Google Scholar 

  • Burstein HJ, Vukelja S, Rugo H, Vogel C, Borson R, Tan-Chiu E, Birkner M, Holden SN, Klencke B, O’Shaughnessy J, Burris HA (2010) A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer. JCO (in press)

    Google Scholar 

  • Conte PF et al. (1996) Activity and safety of epirubicin plus paclitaxel in advanced breast cancer. Semin Oncol 23[Suppl 1]: 28–32

    Google Scholar 

  • Conte PF, Gennari A, Landucci E, Orlandini C (2000) Role of epirubicin in advanced breast cancer. Clin Breast Cancer 1[Suppl 1]: S46–S51

    Article  PubMed  Google Scholar 

  • Doroshaw JH, Leong L, Morolin K et al. (1989) Refractory metastatic breast cancer: salvage therapy with fluorouracil and high dose continuous leucovorine. JCO 7: 439

    Google Scholar 

  • Dowsett M et al. (2005) Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 23: 7512–7517

    Article  CAS  PubMed  Google Scholar 

  • Dowsett M et al. (1996) The control and biological importance of intratumoural aromatase in breast cancer. J Steroid Biochem Mol Biol 56: 145–150

    Article  CAS  PubMed  Google Scholar 

  • Falkson G et al. (1991) Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study. J Clin Oncol 9: 2153–2161

    CAS  PubMed  Google Scholar 

  • Fossati R et al. (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31, 510 women. J Clin Oncol 16: 3439–3460

    CAS  PubMed  Google Scholar 

  • Frickhofen N, Beck FJ, Jung H-G, Fuhr H, Andrasch H, Siegmund M (2002) Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 13: 797

    Article  CAS  PubMed  Google Scholar 

  • Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26): 2733–43

    Article  CAS  PubMed  Google Scholar 

  • Gianni L et al. (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688–2699

    CAS  PubMed  Google Scholar 

  • Giordano SH, Budzdar, AU, Kau, S-W, Hortobagyi GN (2002) Improvement in breast cancer survival: results from MD Anderson Cancer Center protocols from 1975-2000. Proc Am Soc Oncol 21: 212 (Abstract)

    Google Scholar 

  • Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O’Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31): 7794–803

    Article  CAS  PubMed  Google Scholar 

  • Heidemann E et al. (2002) Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Ann Oncol 13: 1717–1729

    Article  CAS  PubMed  Google Scholar 

  • Heinemann V (2003) Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology 64: 191

    Article  CAS  PubMed  Google Scholar 

  • Henderson IC, Allegra JC, Woodcock T, Wolff S, Bryan S, Cartwright K, Dukart G, Henry D (1989) Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560–571

    CAS  PubMed  Google Scholar 

  • Holdaway IM, Bowditch JV (1983) Variation in receptor status between primary and metastatic breast cancer. Cancer 52: 479–485

    Article  CAS  PubMed  Google Scholar 

  • Holmes FA (1996) Paclitaxel combination therapy in the treatment of metastatic breast cancer. Semin.Oncol. 23[Suppl 12]: 29–39

    CAS  PubMed  Google Scholar 

  • Hortobagyi GN, Holmes FA (1997) Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer. Semin Oncol 24[Suppl 3]: S4–S7

    CAS  PubMed  Google Scholar 

  • Hortobagyi GN et al. (1983) Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1: 776–786

    CAS  PubMed  Google Scholar 

  • Hortobagyi GN, Yap HY, Kau S-W et al. (1989) A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. American J Clin Oncol 12: 57

    Article  CAS  Google Scholar 

  • Howell A et al. (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365: 60–62

    Article  CAS  PubMed  Google Scholar 

  • Howell A et al. (2002) Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396–3403

    Article  CAS  PubMed  Google Scholar 

  • Howell A et al. (2004) Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22: 1605–1613

    Article  CAS  PubMed  Google Scholar 

  • Ingle JN et al. (1986) Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4: 178–185

    CAS  PubMed  Google Scholar 

  • Jassem J, Pienkowski T, Pluzanska A et al. (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. JCO 15: 1707–1715

    Google Scholar 

  • Joensuu H, Holli K, Heikkinen M, Suonio E, Aro AR, Hietanen P, Huovinen R (1998) Combination chemotherapy versus singleagent therapy as first-and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 16: 3720–3730

    CAS  PubMed  Google Scholar 

  • Jones SE et al. (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23: 5542–5551

    Article  CAS  PubMed  Google Scholar 

  • Kaufmann M et al. (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 18: 1399–1411

    CAS  PubMed  Google Scholar 

  • Klijn JGM, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus lhrh agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19: 343–353

    CAS  PubMed  Google Scholar 

  • Koenig H, Patel A (1970) The acute cerebellar syndrom in 5-flourouracil chemotherapy: a manifestation of fluoroacetat intoxication. Neurology 20: 416

    CAS  PubMed  Google Scholar 

  • Kreienberg, R, Kopp I, Lorenz W et al. (2004) Diagnostik, Therapie und Nachsorge des Mammakarzinoms der Frau. Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der beteiligten medizinisch-wissenschaftlichen Fachgesellschaften. Eine nationale S3-Leitlinie

    Google Scholar 

  • Kuzu ME, Albain KS, Huntington MO et al. (2000) A phase II trial of docetaxel and Herceptin in metastatic breast cancer patients overexpressing HER2. Proc Am Soc Oncol 19: 131a

    Google Scholar 

  • Levine MN et al. (1998) Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16: 2651–2658

    CAS  PubMed  Google Scholar 

  • Locker GJ, Wenzel C, Schmiedinger M et al. (2001) Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients. Anticancer Drugs 12: 209

    Article  CAS  PubMed  Google Scholar 

  • Loesch D, Robert N, Asmar L et al. (2002) Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol 15: 3857–3864

    Article  Google Scholar 

  • Lück HJ, Roche H (2002) Weekly paclitaxel: an effective and welltolerated treatment in patients with advanced breast cancer. Crit Rev Oncol Hematol 44 [Suppl]: S15–S30

    Article  PubMed  Google Scholar 

  • Lück HJ, Thomssen C, du Bois A et al. (1996) Interim analysis of a phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer. Sem Oncology 23[Suppl 1]: 33–36

    Google Scholar 

  • Lück HJ, Thomssen C, Untch M et al. (2000) Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/Paclitaxel (ET) vs Epirubicin/Cyclophosphamide (EC). A study of the Ago Breast Cancer Group. Proc Am Soc Oncol 19: 2000 (Abstract 280)

    Google Scholar 

  • Lück H, Minckwitz GV, Du Bois A, Schrader I, Huober J, Heilmann V, Beckmann M, Stähle A, Jackisch C, Marth C, Richter B (2006) Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): A prospective, randomized multicentre phase III study of the AGO breast cancer study group. ASCO Annual Meeting Proceedings. J Clin Oncol 24: 517

    Article  Google Scholar 

  • Mackey JR, Paterson AG, Dirix L, Dewar J et al. (2002) Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Oncol 21 (Abstract 35a)

    Google Scholar 

  • Marty M, Cognetti F, Maraninchi D et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 Study Group. J Clin Oncol 23: 4265–4274

    Article  CAS  PubMed  Google Scholar 

  • Masamura S et al. (1997) Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: Role of very high affinity tissue uptake. Breast Cancer Res Treat 42: 215–226

    Google Scholar 

  • McGuire WL (1973) Estrogen receptors in human breast cancer. J Clin Invest 52: 73–77

    Article  CAS  PubMed  Google Scholar 

  • Messori A, Cattel F, Trippoli S, Vaiani M (2000) Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol. Anticancer Drugs 11: 701–706

    Article  CAS  PubMed  Google Scholar 

  • Miles DW, Chan A, Romieu G, Dirix L, Cortes J, Pivot X, Tomczak P, Juozaityte E, Harbeck N, Steger G, The BO17708 Study Group (2009) Final overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC). SABCS 2009, Abstract 41

    Google Scholar 

  • Milla-Santos A, Milla MD, Lidon MD et al. (2003) Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. Am J Clin Oncol 26: 317–322

    Article  CAS  PubMed  Google Scholar 

  • Miller JJ III, Williams GF, Leissring JC (1971) Multiple late complications of therapy with cyclophosphamide. Ann Intern Med. 50: 530

    Google Scholar 

  • Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23(4): 792–9

    Article  CAS  PubMed  Google Scholar 

  • Miller KD, Wang M, Gralow J et al. (2005) A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 94[Suppl 1 ]: 792–799

    Google Scholar 

  • Miller KD, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26): 2666–76

    Article  CAS  PubMed  Google Scholar 

  • Minotti G, Saponiero A, Livata S, Menna P, Calafiore AM, Teodori G, Gianni L (2001) Paclitaxel and Docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res 7: 1511–1515

    CAS  PubMed  Google Scholar 

  • Mouridsen H et al. (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21: 2101–2109

    Article  CAS  PubMed  Google Scholar 

  • Nabholtz JM et al. (2003) Anastrozole (ArimidexTM) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 39: 1684–1689

    Article  CAS  PubMed  Google Scholar 

  • Nabholtz JM, Pienkowski T, Northfelt D et al. (2001) Results of two open label multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (cis or carboplatin) (TCH) as therapy for advanced breast cancer (ABC) in women with tumors overexpressing the HER2-neu protooncogene. Eur J Cancer 37[Suppl 6]: 190 (Abstract)

    Article  Google Scholar 

  • Obermair A, Binder M, Barrada M et al. (1998) Oncholysis in patients treated with docetaxel [letter]. Ann Oncol 9: 230

    Article  CAS  PubMed  Google Scholar 

  • O’Shaughnessy J et al. (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase iii trial results. J Clin Oncol 20: 2812–2823

    Article  PubMed  Google Scholar 

  • Osborne CK et al. (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20: 3386–3395

    Article  CAS  PubMed  Google Scholar 

  • Paridaens R et al. (2003) Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14: 1391–1398

    Article  CAS  PubMed  Google Scholar 

  • Pegram M, Lipton A, Hayes D et al. (1998) Phase II study of receptor enhanced chemosensitivity using recombinant huminized anti-p1 85HER2/neu monoclonal antibody plus cisplatin in patients with HER-2(neu overexpressing metastatic breast cancer. J Clin Oncol 16: 2671

    Google Scholar 

  • Pegram MD et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15: 537–547

    Google Scholar 

  • Perez EA (2004) Carboplatin in combination therapy for metastatic breast cancer. Oncologist 9: 518–527

    Article  CAS  PubMed  Google Scholar 

  • Perez EA et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19: 4216–4223

    Google Scholar 

  • Perez JE, Machiavelli M, Leone BA et al. (1990) Bone-only vs. visceral-only metastatic pattern in breast cancer: analysis of 150 patients.A GOCS Study: Grupo Oncologico Cooperativo del Sur. Am J Clin Oncol 13: 294

    Article  CAS  PubMed  Google Scholar 

  • Piccart MJ, Klijn J, Paridaens R et al. (1997) Corticosteroids significantly delay the onset of docetaxel-induced fluid retentions: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Brunch of Breast Cancer. JCO 15: 3149

    CAS  Google Scholar 

  • Qu G, Perez E (2002) Gemcitabine and targeted therapy in metastatic breast cancer. Sem Oncol 29: 44

    CAS  Google Scholar 

  • Ravidin PM, Valero V (1995) Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer. Semin Oncol 22[Suppl 4]: 17–21

    Google Scholar 

  • Robert N, Leyland-Jones B, Asmar L et al. (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24: 2786

    Article  CAS  PubMed  Google Scholar 

  • Rowinsky EK, Cazenave LA, Donehower RC et al. (1990) Taxol: a novel investigational antimicrotubule agent. J Nat Cancer Inst 82: 1247

    Article  CAS  PubMed  Google Scholar 

  • Rowland KM, Suman VJ, Ingle JN et al. (2003) NCCTG 98-32-52: Randomized phase II trial of weekly versus 3-week administration of paclitaxel, carboplatin and trastuzumab in women with HER2 positive metastatic breast cancer (MBC). Proc Am Soc Oncol 22: 31 (Abstract)

    Google Scholar 

  • Santner SJ et al. (1997) Aromatase activity and expression in breast cancer and benign breast tissue stromal cells. J Clin Endocrinol Metab 82: 200–208

    Article  CAS  PubMed  Google Scholar 

  • Sauer-Heilbron A, Kath R, Schneider CR et al. (1999) Severe non-hematological toxicity after treatment with gemcitabine. Cancer Res Clin Oncol 125: 637

    Article  Google Scholar 

  • Slamon DJ, Clark GM (1988) Amplification of c-erbB-2 and aggressive human breast tumors? Science 240: 1795–1798

    Article  CAS  PubMed  Google Scholar 

  • Slamon DJ et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792

    Article  CAS  PubMed  Google Scholar 

  • Sledge GW et al. (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1 193). J Clin Oncol 21: 588–592

    Article  PubMed  Google Scholar 

  • Sparano JA, Wang M, Martino S et al. (2005) Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1 199. Program and abstracts of the 28th Annual San Antonio Breast Cancer Symposium. Abstract #48

    Google Scholar 

  • Swenerton KD et al. (1979) Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39: 1552–1562

    CAS  PubMed  Google Scholar 

  • Tormey DC, Simon RM, Lippman ME (1976) Evaluation of tamoxifen dose in advanced breast cancer: a progess report. Cancer Treat Rep 60: 1451

    CAS  PubMed  Google Scholar 

  • Tripathy D (2002) Gemcitabine in breast cancer: future directions. Clin Breast Cancer 3[Suppl 1]: 45

    Article  PubMed  Google Scholar 

  • Uber KA, Nicholson BP, Thor AD et al. (2001) A phase II trial of weekly docetaxel (D) and Herceptin (H) as first or second line treatment in HER2 overexpressing metastatic breast cancer. Proc Am Soc Oncol 19: 50b

    Google Scholar 

  • Untch M, Eidtmann H, du Bois A et al. (2004) Cardiac safty of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I study. Eur J Cancer 40: 988

    Article  CAS  PubMed  Google Scholar 

  • Valagussa P, Tancini G, Bonadonna G (1986) Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 58: 1411

    Article  CAS  PubMed  Google Scholar 

  • Vogel CL et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719–726

    Article  CAS  PubMed  Google Scholar 

  • von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 27(12): 1999–2006

    Article  Google Scholar 

  • Wacker A, Lersch CH, Scherpinski U, Reindl L, Seyfarth L (2003) High incidence of angina pectoris in patients treated with 5-fluorouracil. Oncology 65: 108–112

    Article  CAS  PubMed  Google Scholar 

  • Ward WHC (1973) Anti oestrogen therapy for breast cancer: a trial of tamoxifen of two dose levels. BMJ 1: 13

    Article  CAS  PubMed  Google Scholar 

  • Winer E, Burstein H (2001) New combinations with herceptin in metastatic breast cancer. Oncology 61[Suppl 2]: 50–57

    Article  CAS  PubMed  Google Scholar 

  • Yamamoto N et al. (1998) Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 16: 2401–2408

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pelikanplatz 23, 30177, Hannover

    Prof. Dr.med. Hans-Joachiam Lück

Authors
  1. Prof. Dr.med. Hans-Joachiam Lück
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg New York

About this chapter

Cite this chapter

Lück, HJ. (2010). Systemische Therapie des metastasierten Mammakarzinoms. In: Mammakarzinom Interdisziplinär. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12681-9_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-12681-9_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-12680-2

  • Online ISBN: 978-3-642-12681-9

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation